On May 21, 2026 Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, reported that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting in Chicago, taking place May 29 – June 2. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte’s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The OPTIMA study is a prospective, randomized trial led by University College London (UCL) and supported by the National Institute for Health Research (NIHR). The study enrolled more than 4,400 patients and was designed to address a key clinical question: which patients would benefit from chemotherapy, and which may be able to safely avoid it, and its long-term toxicities. The study results demonstrating how the Prosigna test can guide adjuvant chemotherapy decisions in patients with high-risk breast cancer will be presented by Dr. Rob Stein of UCL and OPTIMA Trial Chief Investigator, on Saturday, May 30 during the breast cancer session.

"The OPTIMA trial results represent a major milestone in precision breast oncology and will provide Level 1A evidence supporting Prosigna-guided treatment decisions," said Kelly Marcom, M.D., Veracyte’s medical director, Breast Cancer. "These findings have the potential to transform how clinicians treat a large population of patients with breast cancer, helping them to personalize their patient’s treatment choices using the genomic insights that the Prosigna test provides."

The ENZAMET trial is an international, prospective, randomized study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Dr. Christopher Sweeney of South Australian Immunogenomics Cancer Institute, Adelaide University, will present data on Saturday, May 30 during the Genitourinary Cancer session on Decipher Prostate’s ability to predict treatment benefit with the chemotherapy docetaxel in metastatic, hormone-sensitive prostate cancer. The independent analysis evaluated how the Decipher test can help identify which patients are most likely to benefit from treatment intensification with triplet therapy (docetaxel to standard of cancer hormonal therapy).

"Together, these studies provide practice-changing evidence supporting the use of Veracyte’s tests in guiding treatment decisions across cancer types," said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. "In practice, this means clinicians can more confidently match treatment intensity to individual patient risk, helping ensure the right level of care while avoiding unnecessary treatment and its side effects, for both breast and prostate cancer patients."

Additional research to be presented at ASCO (Free ASCO Whitepaper) supports the company’s mission to transform cancer care for patients all over the world.

Oral Presentations at ASCO (Free ASCO Whitepaper) 2026 Annual Meeting

Title: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer
Presenter: Robert Stein, PhD, MBBChir, FRC, National Institute for Health Research University College London Hospitals Biomedical Research Centre
Session Title: Breast Cancer—Local/Regional/Adjuvant
Date/Time: Saturday, May 30, 2026, 1:15 PM CT
Location: Hall B1
Title: Clinico-Transcriptomic Risk Stratification to Guide Abiraterone Treatment Intensification in High-Risk Prostate Cancer: A Combined Analysis of NRG/RTOG 9202, 9413, 9902, and 0521
Presenter: Krishnan R Patel, MD, MHS, Radiation Oncology Branch, National Cancer Institute, NIH
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Date/Time: Saturday, May 30, 2026, 3:00 PM CT
Location: Hall D1
Title: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study
Presenter: Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Date/Time: Saturday, May 30, 2026, 3:12 PM CT
Location: Hall D1
Title: Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer
Presenter: Daniel Keizman, MD, Tel Aviv Sourasky Medical Center, Israel
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Date/Time: Sunday, May 31, 2026, 4:36 PM CT
Location: Hall D1
Additional Posters at ASCO (Free ASCO Whitepaper)

Abstract #1660 | Poster bd #578: Titled: Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: a national real-world data analysis. Presenter: James Janopaul-Naylor – Saturday May 30, 2026 at 9:00 AM CDT, Hall A
Abstract #4619 | Poster bd #98: Titled: Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial. Presenter: Brigida A. Maiorano – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A
Abstract #5114 | Poster bd #209: Titled: Assessing the Clinical and Biological Associations Between Artera Multimodal Artificial Intelligence (MMAI) and Decipher Genomic Classifier (GC) in Localized Prostate Cancer (PCa). Presenter: Boon Hao Hong – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A
Abstract #4617 | Poster bd #96: Titled: Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC). Presenter: Andrea Necchi – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A
For more information, stop by Veracyte’s booth #13069 at the ASCO (Free ASCO Whitepaper) Annual Meeting or visit the company’s website here.

(Press release, Veracyte, MAY 21, 2026, View Source [SID1234665938])